Zydus Healthcare launches generic anti-diabetic Dapagliflozin tablets in India.

     Zydus Healthcare launched its Dapagliflozin in two variants, 10mg and 5mg with  Rs17 and Rs14 respectively.  

New Delhi: Leading Medicine Manufacturing company Zydus launches Dapagliflozin tablets, across the country with the brand name “Dapaglyn” at a very pocket-friendly cost.

                                       

        This medicine daily prescribed as an adjuvant to diet and exercise, and the main purpose to control the glycemic level in adults suffering from type 2 diabetes mellitus, Zydus healthcare explained.

        Zydus launched this anti-diabetic medicine in two strengths of 10mg and 5mg with price Rs. 17 and Rs 14 respectively, which priced at ⅓ cost than currently available medicine. Due to this reason, this therapy becomes very economical, easily accessible, and very affordable to Patients.


How does Dapagliflozin act on the human body?


        Dapagliflozin is the newly invented class named by sodium-glucose co-transporter 2 (SGLT2)  inhibitors, this drug blocks type 2 of sodium-glucose transporter. Which helps in 90% glucose reabsorption in the body. Due to the blocking of this transporter, results in the high amount of elimination of blood glucose through the urine.  

        Excretion: Urine (75%), feces (21%)




            Dapagliflozin is the first in a novel class of glucose-lowering agents known as sodium-glucose co-transporter-2 (SGLT2) inhibitors and is used in the treatment of patients with type 2 diabetes. By inhibiting the transporter protein SGLT2 in the kidneys, dapagliflozin reduces renal glucose reabsorption, leading to urinary glucose excretion and a reduction in blood glucose levels.


            The results of phase III clinical trials showed that dapagliflozin, at a dose of 5 or 10mg/day for 24 weeks as monotherapy in previously untreated patients, or as add-on combination therapy with metformin, glimepiride, pioglitazone or insulin-based therapy, significantly reduced both HbA1c and fasting plasma glucose levels compared with placebo. In addition, dapagliflozin was non-inferior to glipizide, in terms of glycemic control after 52 weeks, when used as add-on therapy in patients with type 2 diabetes inadequately controlled with metformin. 

                                     

In most clinical trials, dapagliflozin reduced body weight. The combination of both effects (improved glycemic control and weight loss) is achieved to a greater extent in treatments that include dapagliflozin. Longer-term extension studies indicated that the efficacy of dapagliflozin on the glycemic control and weight reducción is maintained for up to 2 and 4 years. Dapagliflozin was well tolerated. Genital infections and urinary tract infections were more frequent in patients who received dapagliflozin than in placebo recipients. Hypoglycemic episodes were scarce with dapagliflozin. In conclusion, dapagliflozin is a novel option for the management of type 2 diabetes, particularly when used as add-on therapy.


Comments

Popular Posts

REMDESIVIR - A BURNING TOPIC

Corona Virus (COVID-19). (Detailed through WHO )

Thyroid Hormones [I]

CEPHALOSPORIN : ANTIBIOTIC